ventilatorassoci
pneumonia
vap
one
common
infect
occur
mechan
ventil
patient
frequent
caus
antibioticresist
bacteria
mortal
hospit
length
stay
health
care
cost
typic
greater
among
patient
respiratori
failur
complic
vap
compar
patient
develop
vap
moreov
know
administr
inappropri
initi
antibiot
therapi
iiat
vap
usual
attribut
multidrugresist
mdr
bacteria
associ
greater
hospit
mortal
longer
hospit
length
stay
outcom
influenc
characterist
vap
make
import
infect
intensivist
manag
optim
manner
ideal
manag
vap
requir
intens
care
unit
icu
hospit
consensusderiv
strategi
place
prevent
diagnosi
treatment
import
nosocomi
infect
unfortun
often
lack
moreov
overal
perceiv
clinic
import
vap
diminish
unit
state
due
imprecis
undercod
nosocomi
infect
use
abstract
antibiot
resist
emerg
key
determin
outcom
patient
seriou
infect
along
virul
underli
pathogen
within
intens
care
unit
icu
set
ventilatorassoci
pneumonia
vap
common
nosocomi
infect
frequent
caus
multidrugresist
bacteria
antimicrobi
resist
grow
challeng
care
critic
ill
patient
escal
rate
antibiot
resist
add
substanti
morbid
mortal
cost
relat
infect
icu
gramposit
organ
methicillinresist
staphylococcu
aureu
vancomycinintermedi
aureu
gramneg
bacteria
includ
pseudomona
aeruginosa
acinetobact
speci
carbapenemresist
enterobacteriacea
klebsiella
pneumonia
carbapenemaseproduc
bacteria
extend
spectrum
organ
contribut
escal
rate
resist
seen
vap
nosocomi
infect
rise
rate
antimicrobi
resist
led
routin
empir
administr
broadspectrum
antibiot
even
bacteri
infect
document
moreov
sever
new
broaderspectrum
antibiot
recent
becom
avail
other
schedul
approv
near
futur
challeng
icu
clinician
effect
util
agent
maxim
patient
benefit
minim
emerg
resist
use
rapid
diagnost
may
hold
key
achiev
import
balanc
urgent
need
integr
administr
new
exist
antibiot
emerg
rapid
diagnost
technolog
way
costeffect
sustain
long
run
ventilatorassoci
pneumonia
vap
one
common
infect
occur
mechan
ventil
patient
frequent
caus
antibioticresist
bacteria
mortal
hospit
length
stay
health
care
cost
typic
greater
among
patient
respiratori
failur
complic
vap
compar
patient
develop
vap
moreov
know
administr
inappropri
initi
antibiot
therapi
iiat
vap
usual
attribut
multidrugresist
mdr
bacteria
associ
greater
hospit
mortal
longer
hospit
length
stay
outcom
influenc
characterist
vap
make
import
infect
intensivist
manag
optim
manner
ideal
manag
vap
requir
intens
care
unit
icu
hospit
consensusderiv
strategi
place
prevent
diagnosi
treatment
import
nosocomi
infect
unfortun
often
lack
moreov
overal
perceiv
clinic
import
vap
diminish
unit
state
due
imprecis
undercod
nosocomi
infect
use
keyword
rapid
diagnost
antibiot
resist
microbiolog
outcom
abstract
antibiot
resist
emerg
key
determin
outcom
patient
seriou
infect
along
virul
underli
pathogen
within
intens
care
unit
icu
set
ventilatorassoci
pneumonia
vap
common
nosocomi
infect
frequent
caus
multidrugresist
bacteria
antimicrobi
resist
grow
challeng
care
critic
ill
patient
escal
rate
antibiot
resist
add
substanti
morbid
mortal
cost
relat
infect
icu
gramposit
organ
methicillinresist
staphylococcu
aureu
vancomycinintermedi
aureu
gramneg
bacteria
includ
pseudomona
aeruginosa
acinetobact
speci
carbapenemresist
enterobacteriacea
klebsiella
pneumonia
carbapenemaseproduc
bacteria
extend
spectrum
organ
contribut
escal
rate
resist
seen
vap
nosocomi
infect
rise
rate
antimicrobi
resist
led
routin
empir
administr
broadspectrum
antibiot
even
bacteri
infect
document
moreov
sever
new
broaderspectrum
antibiot
recent
becom
avail
other
schedul
approv
near
futur
challeng
icu
clinician
effect
util
agent
maxim
patient
benefit
minim
emerg
resist
use
rapid
diagnost
may
hold
key
achiev
import
balanc
urgent
need
integr
administr
new
exist
antibiot
emerg
rapid
diagnost
technolog
way
costeffect
sustain
long
run
center
diseas
control
prevent
surveil
definit
result
promot
ventilatorassoci
event
vae
prefer
surveil
tool
assess
qualiti
icu
care
unit
state
reduc
vap
nonreport
condit
may
encourag
suboptim
practic
vap
treatment
could
detriment
patient
outcom
promot
antibiot
resist
clinic
import
vap
demonstr
recent
surveil
studi
show
common
nosocomi
infect
across
contin
moreov
emerg
problem
antibiot
resist
ad
new
premium
import
accur
diagnos
importantli
treat
vap
appropri
initi
antibiot
therapi
also
imper
recogn
one
major
clinic
issu
relat
manag
vap
well
nosocomi
infect
increas
preval
mdr
extrem
drugresist
xdr
pathogen
appear
direct
relationship
overal
antibiot
consumpt
vap
emerg
newli
resist
bacteri
strain
latest
fearsom
exampl
trend
due
larg
part
escal
use
colistin
emerg
plasmidmedi
colistin
resist
develop
colistin
resist
carbapenemresist
enterobacteriacea
includ
new
delhi
strain
bring
renew
sens
urgenc
minim
resist
emerg
prevent
spread
xdr
bacteria
result
trend
increas
antibiot
resist
boarder
spectrum
empir
antibiot
treatment
suspect
vap
precis
rapid
microbiolog
diagnost
approach
antibiot
manag
suspect
vap
urgent
need
diagnosi
vap
problemat
noninfecti
condit
caus
pulmonari
infiltr
system
find
leukocytosi
fever
increas
oxygen
requir
variou
diagnost
criteria
variabl
rigor
develop
assist
diagnosi
vap
howev
stringent
criteria
avail
associ
greatest
observ
mortal
establish
diagnosi
vap
took
significantli
longer
appli
compar
less
stringent
criteria
potenti
result
delay
therapi
er
side
caution
clinician
employ
find
new
progress
radiograph
infiltr
least
one
clinic
featur
fever
leukocytosi
worsen
oxygen
purul
tracheal
secret
high
sensit
low
specif
vap
difficulti
reli
clinic
criteria
diagnosi
vap
potenti
diagnosi
result
unnecessari
administr
antibiot
noninfect
patient
potenti
promot
emerg
antibiot
resist
especi
employ
prolong
time
period
dilut
abil
clinician
identifi
benefici
impact
treat
patient
appropri
initi
antibiot
therapi
owe
lack
proven
diagnost
method
two
differ
strategi
use
compar
use
clinic
bacteriolog
criteria
associ
advantag
disadvantag
clinic
strategi
employ
abovement
clinic
radiograph
criteria
diagnos
vap
combin
two
three
clinic
criteria
radiograph
infiltr
yield
sensit
specif
diagnosi
vap
mechan
ventil
patient
use
histolog
quantit
lung
tissu
cultur
autopsi
refer
increas
number
clinic
criteria
result
greater
specif
cost
lesser
overal
sensit
postmortem
analysi
mechan
ventil
patient
clinic
criteria
provid
reliabl
predict
accuraci
histolog
pneumonia
semiquantit
endotrach
aspir
cultur
use
identifi
caus
pathogen
vap
posit
shown
correl
quantit
cultur
lower
respiratori
tract
obtain
via
protect
specimen
brush
psb
addit
neg
endotrach
aspir
cultur
good
neg
predict
valu
exclud
presenc
vap
antibiot
recent
start
chang
howev
semiquantit
cultur
gener
reliabl
quantit
cultur
lower
respiratori
tract
due
inabl
differenti
colon
infect
use
clinic
criteria
relianc
semiquantit
cultur
result
clinic
falseposit
result
diagnosi
vap
result
unnecessari
antibiot
use
bacteriolog
strategi
use
quantit
cultur
obtain
lower
respiratori
tract
via
endotrach
aspir
psb
bronchoalveolar
lavag
bal
confirm
exclud
diagnosi
nosocomi
pneumonia
base
threshold
bacteri
growth
coloni
form
unit
cfu
ml
endotrach
aspir
cfuml
bal
specimen
cfuml
psb
sampl
result
procedur
guid
decis
initi
stop
antibiot
drug
use
offend
agent
definit
data
support
use
one
sampl
techniqu
anoth
howev
cellular
analysi
bal
fluid
may
provid
advantag
sampl
contain
less
neutrophil
associ
excel
neg
predict
valu
one
studi
also
given
multifoc
natur
vap
even
minib
sampl
obtain
blindli
without
use
bronchoscopi
effect
howev
studi
caution
use
unilater
cultur
even
direct
side
domin
radiograph
abnorm
bacteriolog
strategi
result
less
overal
prescript
narrow
antibiot
use
import
point
given
surg
antibiot
resist
icu
set
major
disadvantag
bacteriolog
approach
concern
fals
neg
could
result
case
nosocomi
pneumonia
go
untreat
especi
set
recent
introduc
antibiot
multipl
studi
compar
clinic
bacteriolog
strategi
one
prospect
random
trial
demonstr
mortal
benefit
use
bacteriolog
strategi
day
other
fail
reproduc
find
includ
larg
studi
conduct
canadian
critic
care
trial
group
comprehens
metaanalysi
addit
bacteriolog
strategi
seem
reduc
durat
mechan
ventil
icu
length
stay
decis
employ
either
clinic
bacteriolog
strategi
rest
clinician
casebycas
basi
bronchoscop
sampl
perform
safe
appropri
personnel
avail
reason
util
approach
antibiot
decis
may
chang
base
cultur
result
allow
effect
antimicrobi
deescal
clinic
strategi
use
clinician
reevalu
patient
often
guidanc
antibiot
usag
regardless
diagnost
strategi
unstabl
patient
high
pretest
probabl
nosocomi
pneumonia
initi
empir
antibiot
delay
antibiot
administr
lead
higher
mortal
lack
consist
establish
precis
diagnosi
vap
led
nation
guidelin
reflect
rel
low
accuraci
microbiolog
cultur
diagnost
tool
vap
moreov
contamin
upper
respiratori
tract
pathogen
endotrach
tube
colon
common
tradit
microbiolog
laboratori
flow
gram
stain
cultur
antibiot
suscept
test
requir
least
hour
inform
process
clinic
decis
make
current
limit
establish
rapid
precis
microbiolog
confirm
diagnosi
vap
serv
impetu
develop
new
rapid
diagnost
approach
import
infect
broad
rang
viral
bacteri
pathogen
caus
acut
respiratori
tract
infect
includ
vap
often
similar
clinic
radiograph
present
rapid
detect
caus
pathogen
offer
potenti
provid
time
administr
appropri
antimicrobi
therapi
well
minim
use
broadspectrum
antibiot
justifi
base
microbiolog
evalu
multiplex
realtim
polymeras
chain
reaction
pcr
offer
rapid
detect
broad
array
respiratori
pathogen
optim
antimicrobi
treatment
filmarray
respiratori
panel
rp
biofir
salt
lake
citi
ut
assay
first
fdaclear
assay
qualit
detect
nucleic
acid
target
virus
bacteria
nasopharyng
swab
specimen
filmarray
rp
detect
viral
target
three
bacteri
speci
bordetella
pertussi
chlamydophila
pneumonia
mycoplasma
pneumonia
typic
associ
communityacquir
pneumonia
turnaround
time
approxim
hour
appli
direct
respiratori
specimen
includ
bal
specimen
mechan
ventil
patient
recent
filmarray
rp
employ
demonstr
nonventil
hospitalacquir
pneumonia
hap
episod
associ
respiratori
viru
infect
alon
concomit
viral
bacteri
infect
type
inform
could
import
implic
term
modifi
deescal
antibiot
therapi
new
luminex
nxtag
respiratori
pathogen
panel
nxtagrpp
austin
tx
introduc
highthroughput
system
detect
nucleic
acid
respiratori
virus
includ
pathogen
detect
filmarray
rp
except
b
pertussi
plu
legionella
pneumophila
human
bocaviru
ventilatorassoci
pneumonia
kollef
burnham
assay
make
suitabl
multiplex
platform
routin
screen
respiratori
specimen
hospitalbas
laboratori
moreov
use
multiplex
realtim
pcr
associ
reduc
antibiot
util
patient
evalu
respiratori
tract
infect
demonstr
potenti
valu
antibiot
stewardship
adjunct
anoth
potenti
use
multiplex
realtim
pcr
would
addit
emerg
respiratori
viral
pathogen
panel
facilit
surveil
identifi
patient
new
often
virul
respiratori
viru
syndrom
middl
east
respiratori
syndrom
coronaviru
infect
preclin
evalu
recent
conduct
evalu
perform
cepheid
xpert
mrsasa
ssti
realtim
pcr
assay
cepheid
sunnyval
ca
lower
respiratori
tract
secret
detect
methicillinresist
staphylococcu
aureu
mrsa
aureu
compar
gold
standard
quantit
cultur
sensit
specif
posit
neg
predict
valu
respect
assay
employ
exclud
presenc
mrsa
aureu
vap
demonstr
neg
predict
valu
methicillinsuscept
aureu
mssa
mrsa
respect
new
pointofcar
pcr
system
rapid
identif
pathogen
antibiot
resist
marker
avail
show
promis
manag
infect
like
vap
kunz
et
al
evalu
pointofcar
multiplex
pcr
unyvero
cureti
ag
holzgerlingen
germani
patient
hap
mean
turnaround
test
result
time
hour
hour
multiplex
pcr
hour
hour
convent
microbiolog
howev
found
concord
result
nonconcord
result
patient
result
concord
patient
clinic
pulmonari
infect
score
higher
suggest
high
likelihood
presenc
hap
author
conclud
unyvero
allow
pointofcar
microbi
test
short
turnaround
time
system
perform
poor
need
improv
system
reliabl
perform
extend
microbi
panel
vincent
et
al
employ
cultureindepend
polymeras
chain
reactionelectrospray
ionizationmass
spectrometri
pcresim
test
bloodstream
infect
sampl
pneumonia
sampl
steril
fluid
tissu
specimen
patient
bloodstream
sampl
pcresim
identifi
pathogen
case
convent
cultur
method
convent
specimen
move
seri
reagent
includ
nucleic
acid
extract
purif
step
revers
transcriptas
initi
pcr
step
secondstag
pcr
pcr
product
detect
perform
honeycomb
secondstag
pcr
cultur
posit
pcresim
neg
case
neg
case
give
pcresim
sensit
specif
neg
predict
valu
hour
sampl
acquisit
similar
observ
made
pneumonia
steril
fluid
tissu
specimen
independ
clinic
analysi
result
suggest
pcresim
technolog
could
potenti
result
alter
treatment
patient
find
studi
promis
suggest
clinic
decis
make
could
potenti
influenc
posit
manner
pcresim
allow
rapid
accur
modif
antibiot
therapi
banerje
et
al
perform
random
trial
total
patient
posit
blood
cultur
bottl
bcb
underw
stratifi
random
three
arm
standard
bcb
process
control
n
rapid
multiplex
pcr
report
templat
comment
rmpcr
n
rmpcr
report
templat
comment
realtim
audit
feedback
antimicrobi
order
antimicrobi
stewardship
team
rmpcra
n
primari
outcom
antimicrobi
therapi
durat
rmpcr
panel
use
intervent
arm
filmarray
blood
cultur
id
panel
biofir
biofir
perform
soon
bcb
signal
posit
hour
day
day
week
assay
detect
pathogen
resist
gene
shown
compar
control
group
intervent
group
decreas
broadspectrum
piperacillintazobactam
use
increas
narrowspectrum
antibiot
use
fewer
instanc
antibiot
therapi
contamin
time
gram
stain
appropri
antimicrobi
deescal
escal
shortest
rmpcra
group
aim
would
replic
type
find
patient
pneumonia
use
lower
respiratori
specimen
verigen
nanospher
system
multiplex
nucleic
acid
detect
assay
use
clinic
laboratori
pathogen
identif
resist
gene
detect
posit
blood
cultur
broth
respiratori
pathogen
detect
similar
biofir
blood
cultur
assay
use
verigen
assay
bacterem
patient
associ
reduc
length
stay
reduc
mortal
improv
time
optim
antimicrobi
therapi
panel
direct
toward
lower
respiratori
tract
pathogen
develop
tradit
identif
microb
recov
cultur
reli
microbi
growth
metabol
presenc
variou
biochem
substrat
contrast
matrixassist
laser
desorpt
ioniz
timeofflight
mass
spectrometri
malditof
ms
use
proteom
profil
assign
identif
appli
varieti
microb
includ
bacteria
yeast
mold
mycobacteria
primarili
ribosom
protein
detect
use
method
maldi
biotyp
system
bruker
dalton
billerica
vitek
ms
biomerieux
durham
nc
commerci
avail
malditof
ms
instrumentationdatabas
platform
microorgan
identif
malditof
ms
use
frequent
expedit
identif
microb
recov
solid
cultur
media
also
use
identifi
microb
clinic
specimen
includ
posit
blood
cultur
broth
urin
addit
proofofprincipl
studi
demonstr
power
method
simultan
identifi
import
resist
determin
routin
organ
identif
vancomycinintermedi
aureu
certain
kpccontain
plasmid
technolog
becom
widespread
like
rapid
accur
identif
pathogen
facilit
optim
antimicrobi
therapi
patient
type
infect
includ
respiratori
infect
fluoresc
insitu
hybrid
fish
techniqu
base
fluoresc
label
oligonucleotid
probe
may
et
al
employ
novel
strategi
rapid
diagnosi
vap
util
exhal
breath
condens
fluid
ebcf
obtain
heat
moistur
exchang
provid
substrat
test
pcr
identifi
bacteri
dna
investig
show
critic
ill
surgic
patient
excel
concord
pathogen
identif
use
pcr
ebcf
pathogen
isol
bal
fluid
use
convent
microbiolog
techniqu
addit
found
increas
dna
load
among
serial
ebcf
sampl
preced
clinic
suspicion
vap
potenti
advantag
type
diagnost
approach
includ
noninvas
sampl
ebcf
eas
acquir
serial
sampl
potenti
allow
preemptiv
target
prevent
treatment
earli
vap
tracheobronch
pathogenspecif
character
latter
could
help
direct
antibiot
therapi
limit
unnecessari
use
broadspectrum
antibiot
pathogen
identifi
thu
promot
antibiot
stewardship
principl
main
disadvantag
type
pcrdirect
diagnost
approach
provid
true
antimicrobi
suscept
test
caus
pathogen
volatil
organ
compound
voc
detect
anoth
promis
diagnost
technolog
probabl
greatest
applic
vap
human
bacteria
produc
voc
volatil
carbon
molecul
part
metabol
voc
vari
depend
diseas
state
growth
environ
presenc
bacteria
technolog
particularli
appeal
lung
diseas
monitor
noninvas
analyz
exhal
breath
similar
ebcf
chang
voc
pattern
trigger
earli
workup
also
monitor
assess
respons
treatment
mass
spectrometri
swiftli
identifi
quantifi
voc
new
technolog
like
electron
nose
optic
spectra
system
describ
voc
pattern
fingerprint
bacteria
studi
includ
ventil
patient
electron
nosederiv
voc
fingerprint
show
good
correl
clinic
pneumonia
score
recent
studi
monitor
ventil
patient
thrice
weekli
use
electron
nose
technolog
obtain
voc
fingerprint
abl
differenti
infect
colon
noninfect
patient
potenti
voc
detect
diagnos
lung
infect
use
either
specif
biomark
whole
voc
fingerprint
current
activ
pursu
potenti
limit
implic
novel
diagnost
vap
suggest
earlier
experi
rapid
diagnost
evalu
blood
cultur
specimen
suggest
rapid
diagnost
may
play
import
role
enhanc
antimicrobi
prescrib
practic
hospit
patient
benefit
numer
includ
optim
ventilatorassoci
pneumonia
kollef
burnham
clinic
outcom
reduc
toxic
facilit
clinic
trial
new
antiinfect
agent
stratifi
patient
elig
trial
earliest
possibl
opportun
howev
also
import
understand
limit
new
technolog
includ
differenti
colon
infect
could
highli
problemat
mechan
ventil
patient
give
us
true
suscept
pattern
respons
pathogen
latter
true
except
specif
mechan
resist
provid
previous
describ
molecular
techniqu
autom
microscopi
potenti
provid
real
suscept
data
illustr
potenti
role
rapid
diagnost
improv
antimicrobi
therapi
outcom
embed
wellorgan
antimicrobi
stewardship
program
studi
huang
et
al
univers
michigan
investig
perform
quasiexperiment
studi
analyz
impact
malditof
ms
conjunct
antimicrobi
stewardship
team
intervent
patient
bloodstream
infect
antimicrobi
stewardship
team
provid
antibiot
recommend
receiv
realtim
notif
follow
blood
cultur
gram
stain
organ
identif
antimicrobi
suscept
use
convent
microbiolog
method
beforeperiod
malditof
ms
afterperiod
use
malditof
ms
significantli
decreas
time
organ
identif
improv
time
effect
antibiot
therapi
well
optim
direct
antibiot
therapi
mortal
length
icu
stay
recurr
bacteremia
also
lower
intervent
period
similarli
pcrbase
genexpert
mrsasa
diagnost
platform
cepheid
sunnyval
ca
studi
veteran
affair
medic
center
houston
demonstr
mssa
bacteremia
mean
time
initi
appropri
therapi
reduc
hour
durat
unnecessari
mrsa
drug
therapi
reduc
hour
per
patient
hope
applic
rapid
diagnost
method
respiratori
specimen
could
similar
impact
patient
pneumonia
includ
vap
clear
enter
new
era
manag
treatment
seriou
infect
vap
spellberg
et
al
made
recent
plea
chang
current
pattern
manag
patient
proven
presum
infect
revers
spiral
trend
antibiot
resist
occur
last
centuri
within
next
year
new
antibiot
direct
mdr
gramneg
bacteria
addit
recent
approv
ceftolozanetazobactam
ceftazidimeavibactam
like
becom
avail
includ
carbav
plazomicin
eravacyclin
relebactam
brilacidin
aztreonamavibactam
carbapenem
novel
siderophor
cephalosporin
agent
provid
enhanc
activ
produc
carbapenemresist
bacteria
case
even
bacteria
challeng
icu
clinician
effect
util
agent
becom
avail
maxim
patient
benefit
minim
emerg
resist
especi
import
challeng
resourcelimit
countri
often
forefront
emerg
novel
antimicrobi
resist
mechan
due
local
pattern
antibiot
use
use
rapid
diagnost
may
hold
key
achiev
import
balanc
urgent
need
clinic
studi
aim
understand
best
integr
use
new
antibiot
emerg
rapid
diagnost
technolog
way
costeffect
sustain
long
run
addit
microbiolog
laboratori
must
work
close
clinic
partner
deploy
new
diagnost
tool
manner
afford
maximum
benefit
new
technolog
includ
incorpor
antimicrobi
stewardship
team
interpret
report
comment
applic
clinic
outcom
studi
demonstr
benefit
new
technolog
patient
outcom
need
vap
may
ideal
infect
demonstr
impact
rapid
diagnost
mean
enhanc
antimicrobi
treatment
stewardship
